文献速递前列腺癌

68Ga-PSMA-11 PET/CT预测高危前列腺癌新辅助治疗病理反应

Can 68Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study.
PubMed 文献 · J Urol · 2020-11-18

本研究纳入45例局限高危前列腺癌患者,在6个月新辅助雄激素剥夺联合阿比特龙治疗前后行68Ga-PSMA-11 PET/CT,术后全标本病理评估有利病理反应(完全反应或残留<5mm)。PET/CT反应诊断有利病理反应的特异度显著高于PSA反应(89.7% vs 62.1%,p=0.043),治疗后最大标准化摄取值是多变量分析中唯一独立预测因子(OR 9.69,95%CI 1.439-65.242,p=0.020)。

要点

  • PET/CT反应诊断有利病理反应特异度89.7%,显著高于PSA反应的62.1%。
  • 治疗后最大标准化摄取值是独立预测因子(OR 9.69,95%CI 1.439-65.242)。
  • 治疗后肿瘤体积和术前最低PSA在单变量中与有利病理反应相关。

核心结论

  • 68Ga-PSMA PET/CT对新辅助治疗病理反应的诊断性能优于PSA,最大标准化摄取值是独立预测因子。
  • 该初步研究提示PSMA PET/CT可能作为新辅助治疗病理反应的潜在预测工具。

研究设计与样本

  • 前瞻性初步研究,纳入45例局限高危前列腺癌患者。
  • 患者在6个月雄激素剥夺联合阿比特龙新辅助治疗前后行68Ga-PSMA-11 PET/CT,随后行根治性前列腺切除术。
  • 有利病理反应定义为全标本病理完全反应或残留病灶<5mm。

主要发现

  • PET/CT反应诊断有利病理反应的特异度为89.7%,PSA反应为62.1%,差异显著(p=0.043)。
  • 单变量分析中,术前最低PSA(OR 0.121,95%CI 0.028-0.529,p=0.005)、治疗后最大标准化摄取值(OR 7.072,95%CI 2.035-24.579,p=0.002)和治疗后肿瘤体积(OR 7.896,95%CI 1.415-44.054,p=0.018)与有利病理反应显著相关。
  • 多变量分析中仅治疗后最大标准化摄取值是独立预测因子(OR 9.69,95%CI 1.439-65.242,p=0.020)。

关键数值与推荐

  • 有利病理反应:全标本病理完全反应或残留病灶<5mm。
  • PET/CT反应诊断有利病理反应特异度89.7%,PSA反应特异度62.1%(p=0.043)。

临床怎么用

  • 在高危前列腺癌新辅助治疗决策中,可考虑用68Ga-PSMA PET/CT评估病理反应,尤其关注治疗后最大标准化摄取值。
  • PET/CT反应较PSA反应具有更高特异度,有助于减少误判。

局限性

  • 本研究为初步研究,样本量45例,结论需更大样本验证。
  • 原文未报告敏感性、阳性预测值、阴性预测值等完整诊断性能指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We explored the role of 68Ga-PSMA-11 positron emission/computerized tomography as a predictor of pathological response to neoadjuvant androgen deprivation therapy combined with abiraterone for high risk prostate cancer. MATERIALS AND METHODS: A total of 45 patients with localized high risk prostate cancer who had serial 68Ga-PSMA-11 positron emission tomography/computerized tomography scans before and after 6 months of androgen deprivation therapy plus abiraterone neoadjuvant treatment followed by radical prostatectomy were included in this study. Complete pathological response or minimal residual disease <5 mm on whole mount histopathology was defined as favorable pathological response. The diagnostic performance of prostate specific antigen response and positron emission tomography/computerized tomography response for favorable pathological response was calculated. Univariable and multivariable logistic regression analyses of clinical and imaging variables were also performed to identify favorable pathological response. RESULTS: Compared to the prostate specific antigen response, positron emission tomography/computerized tomography response had a significantly higher specificity in diagnosing favorable pathological response (89.7% vs 62.1%, p=0.043). Preoperative nadir prostate specific antigen (OR 0.121, 95% CI 0.028-0.529, p=0.005), posttreatment maximum standardized uptake value (OR 7.072, 95% CI 2.035-24.579, p=0.002) and posttreatment tumor volume (OR 7.896, 95% CI 1.415-44.054, p=0.018) measured on positron emission tomography/computerized tomography were significantly associated with favorable pathological response in univariable logistic regression analysis. On multivariable logistic regression analysis, only posttreatment maximum standardized uptake value was found to be an independent predictor of favorable pathological response (OR 9.69, 95% CI 1.439-65.242, p=0.020). CONCLUSIONS: 68Ga-PSMA positron emission tomography/computerized tomography has a better diagnostic performance of pathological response to neoadjuvant treatment compared with prostate specific antigen, with maximum standardized uptake value being an independent predictive factor. This pilot study suggests that prostate specific membrane antigen positron emission tomography/computerized tomography may serve as a potential predictor of pathological response to neoadjuvant treatment.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Chen M, Zhuang J, Fu Y, et al. Can 68Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study. J Urol. 2020. PMID: 33207140. doi:10.1097/JU.0000000000001481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。